2.00 -0.05 (-2.44%)
After hours: 4:57PM EDT
|Bid||2.00 x 3000|
|Ask||2.14 x 2900|
|Day's Range||2.01 - 2.11|
|52 Week Range||1.29 - 3.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. With that being said this market could bring incredible value to shareholders of regenerative medicine companies over the next several years. With BioRestorative Therapies, Inc. (BRTX) we noticed that the market cap of this company is so low it could very well have a lot of room to grow.
CLEVELAND, July 10, 2018-- Athersys, Inc. will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7 th, 2018, and will host a conference call shortly ...
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...
Athersys, Inc. (ATHX) announced today that it has entered into an agreement with HEALIOS K.K. (“Healios”) to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome (“ARDS”) and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs.
Athersys, Inc. (ATHX) announced today that it has entered into an agreement with HEALIOS K.K. ("Healios") to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome ("ARDS") and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
Athersys, Inc. (ATHX) announced today its financial results for the three months ended March 31, 2018. Completed a $21.1 million equity investment and announced plans to expand the HEALIOS K.K. ("Healios") collaboration by June 1, 2018.
Assessing Athersys Inc’s (NASDAQ:ATHX) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
CLEVELAND and TOKYO, May 01, 2018-- Athersys, Inc. and HEALIOS K.K. have agreed to extend the period from April 30, 2018 to May 31, 2018 to complete their planned collaboration expansion agreements, as ...
Levi & Korsinsky announces it has commenced an investigation of Athersys, Inc. concerning possible breaches of Delaware law by the board of directors of the company.
NEW YORK, April 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
CLEVELAND, April 23, 2018-- The University of Texas Health Science Center at Houston and Athersys, Inc. today announced plans to conduct a Phase 2 clinical trial evaluating Athersys’ MultiStem ® cell therapy ...
Athersys to Host Conference Call to Announce Phase I Clinical Trial Results Involving MultiStem(R) for Acute Myocardial Infarction
Companies such as inTEST and Energy Recovery have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider theseRead More...